New insights into drug absorption: Studies with sirolimus

Therapeutic Drug Monitoring

Volumn 26, Issue 5, 2004, Pages 463-467

  Paine, Mary F ^a,c   Leung, Louis Y ^b   Watkins, Paul B ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

Efflux; First pass; Intestine; Metabolism; Sirolimus

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450 3A4; DRUG METABOLITE; GLYCOPROTEIN P; RAPAMYCIN; RAPAMYCIN C 14; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SECO RAPAMYCIN; TROLEANDOMYCIN; UNCLASSIFIED DRUG; ZOSUQUIDAR;

APICAL MEMBRANE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG INHIBITION; DRUG ISOLATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SCREENING; DRUG TRANSPORT; FIRST PASS EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; INCUBATION TIME; INTESTINE ABSORPTION; INTESTINE EPITHELIUM CELL; LIVER HOMOGENATE; LIVER MICROSOME; PRIORITY JOURNAL; RING OPENING; SHORT SURVEY; TISSUE HOMOGENATE;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; CARBON RADIOISOTOPES; CYTOCHROME P-450 ENZYME SYSTEM; DIBENZOCYCLOHEPTENES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; P-GLYCOPROTEIN; PERMEABILITY; QUINOLINES; SIROLIMUS; VITAMIN D;

EID: 4744375978     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200410000-00001     Document Type: Short Survey

References (20)

1. Thummel KE, Kunze KL, Shen DD. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev. 1997;27: 99-127.
2. Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica. 2001;31:469-497.
3. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Med. 2001;7: 584-590.
4. 3. Mol Pharmacol. 1997;51:741-754.
5. 3-modified Caco-2 cell monolayers. J Pharmacol Exp Ther. 1999;289:1134-1142.
6. Hochman JH, Chiba M, Nishime J, et al. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther. 2000;292:310-318.
7. Hu M, Li Y, Davitt CM, et al. Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase. Pharm Res. 1999;16:1352-1359.
8. Brimer C, Dalton JT, Zhu Z, et al. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein. Pharm Res. 2000;17:803-810.
9. Cummins CL, Mangravite LM, Benet LZ. Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1, and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Pharm Res. 2001;18:1102-1109.
10. Ferron GM, Mishina EV, Zimmerman JJ, et al. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther. 1997;61:416-428.
11. Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20:753-761.
12. Lampen A, Zhang Y, Hackbarth I, et al. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther. 1998;285:1104-1112.
13. Crowe A, Lemaire M. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res. 1998;15:1666-1672.
14. Paine MF, Leung LY, Lim HK, et al. Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion. J Pharmacol Exp Ther. 2002;301:174-186.
15. Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther. 1997;283:1552-1562.
16. Streit F, Christians U, Schiebel HM, et al. Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (rapamycin) by electrospray-MS/MS after incubation with human liver microsomes. Drug Metab Dispos. 1996;24:1272-1278.
17. Hallensleben K, Raida M, Habermehl G. Identification of a new metabolite of macrolide immunosuppressant, like rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray tandem mass spectrometry. J Am Soc Mass Spectrom. 2000;11:516-525.
18. Cummins CL, Jacobsen W, Christians U, et al. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther. 2004;308: 143-155.
19. Benet LZ, Cummins CL. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev. 2001;50:S3-11.
20. 14C-rapamycin (sirolimus) in healthy male subjects after a single oral dose. ISSX Proc. 1997;12:26.